Researchers from the Department of Chemistry and Warwick Medical School developed a way to synthesize polymers to accelerate antimicrobial activity screening.
Researchers at the University of Warwick have developed a method to synthesize large libraries of polymers to make their screening for antimicrobial activity faster and without the need to use sealed vials, the University announced in an Aug. 14, 2018 press release. The researchers are investigating innovative antimicrobials to address antimicrobial resistance.
The polymers were synthesized using a high-throughput technique with liquid-handling robots and photochemical polymerization. “Whilst many people have successfully mimicked antimicrobial peptides with polymers, the limiting step was the number of different combinations of building blocks you can use. We used simple robotics and a light controlled polymerization, which lets us do the chemistry open to air, without any sealed vials, which are essential for most polymer syntheses,” Professor Matthew Gibson from Warwick’s Department of Chemistry and Warwick Medical School and lead author of a paper published in Chemistry; A European Journal, said in the press release.
“We prepared the polymers in such a way that at the end of the reaction, we use the robotics to mix polymers directly with bacteria, so we could look for unexpected activity, which we achieved,” explained Sarah-Jane Richards, from the Gibson Group at the University of Warwick and the lead author of the work, in the press release. While traditional antimicrobials, such as penicillin, work by inhibiting key cellular processes, the Warwick team is investigating host-defense peptides, which are broad spectrum antimicrobials that function by breaking apart the membrane of bacteria. “Surprisingly, the best materials do not seem to break apart the bacteria as we predicted, but rather inhibit their growth. We are investigating this further," added Richards.
Source: University of Warwick
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.